{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:50:45Z","timestamp":1792705845406,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jhep.2016.12.005","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T07:20:46Z","timestamp":1482045646000},"page":"724-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"title":["The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction"],"prefix":"10.1016","volume":"66","author":[{"given":"Philipp","family":"Schwabl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hambruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit A.","family":"Seeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Garnys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim-Lukas","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Mitteregger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Burnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Oberhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Rohr-Udilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno K.","family":"Podesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Kremoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.12.005_b0005","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0015","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jhep.2013.12.023","article-title":"Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis","volume":"60","author":"Tsochatzis","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0020","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jhep.2011.02.012","article-title":"Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension","volume":"55","author":"Kim","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0030","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.510280405","article-title":"Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats","volume":"28","author":"Gupta","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/gast.1996.v110.pm8566602","article-title":"Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells","volume":"110","author":"Pinzani","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0040","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0045","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0050","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0055","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/liv.12795","article-title":"Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites","volume":"35","author":"Schwabl","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.12.005_b0060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.06.004","article-title":"Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension","volume":"53","author":"de Franchis","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00508-013-0337-z","article-title":"Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)","volume":"125","author":"Peck-Radosavljevic","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jhep.2016.12.005_b0070","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.12.005_b0075","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0080","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.acthis.2007.08.001","article-title":"Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray","volume":"110","author":"Higashiyama","year":"2008","journal-title":"Acta Histochem"},{"key":"10.1016\/j.jhep.2016.12.005_b0090","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0100","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2011.02.044","article-title":"Nuclear receptors as new perspective for the management of liver diseases","volume":"140","author":"Trauner","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2016.12.005_b0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biochi.2015.05.014","article-title":"Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice","volume":"115","author":"Wu","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.jhep.2016.12.005_b0115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0120","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO-3 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0130","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.12.005_b0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.celrep.2014.02.032","article-title":"Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice","volume":"7","author":"Degirolamo","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2016.12.005_b0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2016.12.005_b0145","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2016.12.005_b0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.12.005_b0155","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.12.005_b0160","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.dld.2014.07.008","article-title":"A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis","volume":"46","author":"Lutz","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2016.12.005_b0165","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1053\/jhep.2003.50116","article-title":"Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats","volume":"37","author":"Lorenzo-Z\u00fa\u00f1iga","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2016.12.005_b0175","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0180","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbadis.2011.04.005","article-title":"Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-\u03baB signaling in the intestine","volume":"1812","author":"Gadaleta","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2016.12.005_b0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bbrc.2008.12.117","article-title":"Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists","volume":"379","author":"Zhang","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2016.12.005_b0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvm016","article-title":"FXR-mediated regulation of eNOS expression in vascular endothelial cells","volume":"77","author":"Li","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jhep.2016.12.005_b0195","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2016.12.005_b0200","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2014.08.024","article-title":"Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension","volume":"62","author":"Mookerjee","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0210","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3748\/wjg.15.2097","article-title":"Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation","volume":"15","author":"Renga","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.12.005_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013955","article-title":"Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.12.005_b0220","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","article-title":"Obeticholic acid reduces bacterial translocation and inhibits intestinalinflammation in cirrhotic rats","volume":"64","author":"\u00dabeda","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0225","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-\/-) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2016.12.005_b0230","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmcl.2016.05.070","article-title":"Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties","volume":"26","author":"Kinzel","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jhep.2016.12.005_b0235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","article-title":"Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats","volume":"60","author":"Schwabl","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.005_b0240","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0245","first-page":"1529A","article-title":"Effect of the FXR agonist obeticholic acid on portal pressure in alcoholic cirrhosis: a phase 2 proof of concept study","volume":"56","author":"Mookerjee","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0250","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2174\/1568026614666141112094430","article-title":"Knocking on FXR's door: the \u201chammerhead\u201d-structure series of FXR agonists \u2013 amphiphilic isoxazoles with potent in vitro and in vivo activities","volume":"14","author":"Gege","year":"2014","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jhep.2016.12.005_b0255","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.005_b0260","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2016.12.005_b0265","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1124\/jpet.109.153510","article-title":"Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine","volume":"331","author":"Li","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2016.12.005_b0270","doi-asserted-by":"crossref","first-page":"27038","DOI":"10.1074\/jbc.M802269200","article-title":"Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme","volume":"283","author":"Chen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2016.12.005_b0275","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1093\/emboj\/20.21.6008","article-title":"The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener","volume":"20","author":"Zhao","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.jhep.2016.12.005_b0280","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.510270222","article-title":"Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells","volume":"27","author":"Rockey","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0285","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI118925","article-title":"Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing","volume":"98","author":"Rockey","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.12.005_b0290","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/01.RES.0000200400.55539.85","article-title":"Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells","volume":"98","author":"He","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jhep.2016.12.005_b0295","doi-asserted-by":"crossref","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation andfibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2016.12.005_b0300","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s00535-012-0599-7","article-title":"Combined measurements of serum bile acid level and splenic volume may be useful to noninvasively assess portal venous pressure","volume":"47","author":"Hayashi","year":"2012","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.12.005_b0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.1840060110","article-title":"Prognostic significance of serum bile acids in cirrhosis","volume":"6","author":"Mannes","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.005_b0310","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/toxsci\/kfr177","article-title":"Dose-response of five bile acids on serum andliver bile Acid concentrations and hepatotoxicty in mice","volume":"123","author":"Song","year":"2011","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhep.2016.12.005_b0315","first-page":"1175","article-title":"Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies","volume":"18","author":"Pak","year":"1993","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816307103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816307103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T16:23:59Z","timestamp":1536164639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816307103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0168827816307103"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.12.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727127707.793545269","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}